Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?

• DOI: 10.4174/astr.2023.105.1.31
• Publication Date: 2023-07-10T01:30:48Z
• Authors: Juhyeon Lee; Chan Sub Park; Jeong Hun Oh; In-Chul Park; Min-Ki Seong; Woo Chul Noh; Hyun-Ah Kim
• Keywords: Regimen; Goserelin; Chemotherapy regimen

Whether administering chemotherapy followed by tamoxifen plus a gonadotropin-releasing hormone (GnRH) agonist to treat patients with lower-risk receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer provides greater benefit than GnRH alone remains unclear. This study aimed compare the outcomes of propensity score-matched (PSM) who underwent these types treatment plans.This retrospective included treated at our institution between 2009 and 2019. Eligible had HR-positive, HER2-negative, invasive undergone surgery. There were 579 HER2-negative tamoxifen; pathologic N2 those received neoadjuvant excluded. After 1:1 PSM versus without chemotherapy, 122 from groups analyzed. Survival rates calculated using Kaplan-Meier method compared via log-rank test.After PSM, there no significant differences in several baseline characteristics groups. median follow-up 62.8 months, both demonstrated similar difference disease-free survival (P = 0.596).Patients derived undergoing regimen before receiving therapy forgoing such chemotherapy.